Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05800223

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic Clinical Trial

Official title:
Prospective, Multicenter, Randomized Controlled, Phase III Clinical Study of Armatinib Alone or in Combination With Stereotactic Body Radiotherapy (SRT) for First-line Treatment of Brain Metastases From EGFR-mutated Non-small Cell Lung Cancer

Clinical Trial Summary

Objective:Patients with asymptomatic or minimally symptomatic Stage IV EGFR-positive NSCLC with baseline intracranial metastases. Aim: To investigate the timing, efficacy and safety of radiotherapy in patients with EGFR positive brain metastases treated with armatinib alone or combined with stereotactic radiotherapy. Method: Almonertinib: specification 55mg/tablet; The dosage is 110 mg / day (2 tablets / day) orally once a day; SBRT: 3-5 doses of 27-40 Gy

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05800223
Study type Interventional
Source Shanghai Cancer Hospital, China
Contact
Status Recruiting
Phase Phase 3
Start date January 1, 2023
Completion date December 2028
View Details
See also
  Status Clinical Trial Phase
Completed NCT01523340 - A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Active, not recruiting NCT02035683 - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy N/A
Completed NCT01848613 - Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC Phase 4
Suspended NCT01320501 - Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer Phase 4
Terminated NCT01471964 - Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT06127940 - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation Phase 1
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Terminated NCT03445000 - ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT03386929 - Survival Prolongation by Rationale Innovative Genomics Phase 1/Phase 2
Recruiting NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Phase 1
Terminated NCT01574300 - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Active, not recruiting NCT04646824 - Almonertinib With Chemotherapy in mEGFR NSCLC Phase 2
Completed NCT01966003 - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 3
Recruiting NCT03656094 - Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors Phase 2
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Active, not recruiting NCT03469960 - Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04793815 - Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) N/A
Terminated NCT01380795 - Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas Early Phase 1